Arcus Phase 2 EDGE-Gastric trial in upper GI cancers completed, 332 enrolled
Registry record for the Arcus/Gilead gastric and esophageal cancer study shows completion on September 7, 2026, with the listing last updated October 26, 2026.
Arcus Biosciences had one update of note in its registry records for the week.
- The Phase 2 "EDGE-Gastric" trial testing domvanalimab, zimberelimab, and quemliclustat combinations, with and without FOLFOX chemotherapy, in patients with advanced gastric, GEJ, or esophageal adenocarcinoma is listed as completed. The trial evaluated the safety and preliminary clinical activity of treatment combinations with and without chemotherapy in participants with locally advanced unresectable or metastatic gastric, GEJ, and esophageal adenocarcinoma.1 The registry lists primary completion and study completion both as September 7, 2026, with enrollment of 332 participants (actual)1, and the record's last update was posted October 26, 2026. Arcus Biosciences is the lead sponsor, with Gilead Sciences as a collaborator.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.